Cardiovascular and neurological adverse events associated with antidepressant treatment in children and adolescents

Journal of Child Neurology

Volumn 24, Issue 3, 2009, Pages 297-304

  Jerrell, Jeanette M ^a   McIntyre, Roger S ^b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Cardiovascular adverse events; Neurological adverse events; Serotonin reuptake inhibitors

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXAPRAM; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; METHYLPHENIDATE; MIRTAZAPINE; MOOD STABILIZER; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CHILD; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CONVULSION; DIZZINESS; DRUG EXPOSURE; DRUG INDUCED HEADACHE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSOMNIA; INVOLUNTARY MOVEMENT; MAJOR AFFECTIVE DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DEFICIENCY; NEUROLOGIC DISEASE; ORGANIC BRAIN SYNDROME; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SLEEP APNEA SYNDROME; SOMNOLENCE; SYNCOPE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHILD; COHORT STUDIES; DIZZINESS; FEMALE; HEADACHE; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MEDICAID; MENTAL RETARDATION; RETROSPECTIVE STUDIES; SEIZURES; SEROTONIN UPTAKE INHIBITORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; UNITED STATES;

EID: 62149132118     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808323523     Document Type: Article

References (30)

1. Costello EJ, Erkanli A., Angold A. Is there an epidemic of child or adolescent depression? J Child Psychol Psychiatry. 2006;47:1263-1271.
2. Cohen D., Gerardin P., Mazet P., Purper-Ouakil D., Flament MF Pharmacological treatment of adolescent major depression. J Child Adolesc Psychopharmacol. 2004;14:19-31.
3. Moreno C., Ansley MR, Greenhill LL Pharmacotherapy of child and adolescent depression. Child Adolesc Psychiatr Clin N Am. 2006;15:977-998.
4. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with SSRI treatment for depression: Patient report versus physician estimate. J Clin Psychiatry. 2004;65:959-965.
5. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14:175-182.
6. Michelson D., Faries D., Wernicke J., et al. Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:E83.
7. Pacher P., Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Curr Pharm Des. 2004;10:2463-2475.
8. To SE, Zepf RA, Woods AG The symptoms, neurobiology, and current pharmacological treatment of depression. J Neurosci Nurs. 2005;37:102-107.
9. Ellsworth AJ, Witt DM, Dugdale DC, Oliver LM Mosby's Medical Drug Reference. St Louis: Mosby; 2006.
10. Van Knorring A., Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharm. 2006;26:311-315.
11. Wagner KD, Jonas J., Findling RL, Ventura D., Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280-288.
12. Damsa C., Bumb A., Bianchi-Demicheli F., et al. "Dopamine dependent" side effects of SSRIs: A clinical review. J Clin Psychiatry. 2004;65:1064-1068.
13. Gold Standard, Inc [database]. Citalopram, Escitalopram, Fluoxetine, Fluoxetine+Olanzapine, Fluvoxamine, Paroxetine, and Sertraline: Adverse Reactions. MD Consult. Columbia, SC: University of South Carolina School of Medicine Library; 2008. Accessed January 30, 2008.
14. Coulter DM, Pillans PI Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 1995;152:122-125.
15. Skowron DM, Stimmel GL Antidepressants and the risk of seizures. Pharmacotherapy. 1992;12:18-22.
16. Devane CL, Sallee FR SSRIs in child and adolescent psychiatry: A review of published experience. J Clin Psychiatry. 1996;57:55-66.
17. Magulac M., Landsverk J., Golshan S., Jeste DV Abnormal movements in neuroleptic-naïve children and adolescents. Can J Psychiatry. 1999;44:368-373.
18. Velamoor VR Neuroleptic malignant syndrome: Recognition, prevention, and management. Drug Saf Concept. 1998;19:73-82.
19. Cheng-Shannon J., McGough JJ, Pataki C., McCracken JT Second generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharm. 2004;14:372-394.
20. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15:177-206.
21. McIntyre RS, Konarski JZ Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(suppl 3):28-36.
22. Francis PD Effects of psychotropic medications on pediatric electrocardiogram and recommendations for monitoring. Curr Opin Pediatr. 2002;14:224-230.
23. MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762-769.
24. Keck PE The role of second-generation antipsychotic mono-therapy in the rapid control of acute bipolar mania. J Clin Psychiatry. 2005;66(suppl 3):5-11.
25. Wagner KD, Weller EB, Carlson GA, et al. An open-label trial of divalproex in children and adolescents with bipolar disorder. J Acad Child Adolesc Psychiatry. 2002;41(10):1224-1230.
26. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006;5:157-168.
27. Sorof JM, Daniels S. Obesity hypertension in children: A problem of epidemic proportions. Hypertension. 2002;40:441-447.
28. Flynn JT What's new in pediatric hypertension? Curr Hypertens Rep. 2001;3:503-510.
29. Holmberg SK, Kane C. Health and self-care practices of persons with schizophrenia. Psychiatr Serv. 1999;50:827-829.
30. Mark TL, Buck JA, Dilonardo JD, Coffey RM, Chalk M. Medicaid expenditures on behavioral health care. Psychiatr Serv. 2003;54:188-194.